| scholarly article | Q13442814 |
| P50 | author | Deyin Guo | Q39988945 |
| P2093 | author name string | Jian Huang | |
| Yu Chen | |||
| Wei Hou | |||
| Wenzhe Ho | |||
| Xiao Yu | |||
| Shuliang Chen | |||
| Meng Jiang | |||
| Shilei Wang | |||
| Panpan Hou | |||
| Ke Zhuang | |||
| P2860 | cites work | Non-homologous end joining as a mechanism of DNA repair | Q74185601 |
| Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4(+) T cell resistance and enrichment | Q35876209 | ||
| Change in coreceptor use correlates with disease progression in HIV-1--infected individuals | Q36376800 | ||
| Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice | Q36545262 | ||
| Inhibition of HIV-1 transcription and replication by a newly identified cyclin T1 splice variant. | Q36850296 | ||
| Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells | Q37148527 | ||
| CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity | Q37271186 | ||
| Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection. | Q37429714 | ||
| Diagnosis and management of lymphomas and other cancers in HIV-infected patients | Q38194845 | ||
| CRISPR-Cas9: a new and promising player in gene therapy | Q38364993 | ||
| Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. | Q38889625 | ||
| Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. | Q39028341 | ||
| HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. | Q39593854 | ||
| CXC chemokine receptor 4 expressed in T cells plays an important role in the development of collagen-induced arthritis | Q41555285 | ||
| A novel approach to block HIV-1 coreceptor CXCR4 in non-toxic manner | Q42217563 | ||
| Inhibition of human immunodeficiency virus type-1 (HIV-1) replication at a reverse transcription step by human cell factor(s). | Q45472079 | ||
| Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy | Q45760702 | ||
| The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway | Q22065419 | ||
| The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry | Q24315492 | ||
| Multiplex genome engineering using CRISPR/Cas systems | Q24609428 | ||
| RNA-guided editing of bacterial genomes using CRISPR-Cas systems | Q24630389 | ||
| CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression | Q24635943 | ||
| Pre-clinical modeling of CCR5 knockout in human hematopoietic stem cells by zinc finger nucleases using humanized mice | Q26862954 | ||
| Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV | Q28235281 | ||
| Development and applications of CRISPR-Cas9 for genome engineering | Q28241526 | ||
| The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus | Q28259668 | ||
| Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation | Q28300338 | ||
| HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy | Q28339571 | ||
| CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection | Q28542878 | ||
| CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1 | Q28646859 | ||
| Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection | Q29614956 | ||
| Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation | Q29615068 | ||
| Recovery of replication-competent HIV despite prolonged suppression of plasma viremia | Q29615995 | ||
| Improving CRISPR-Cas nuclease specificity using truncated guide RNAs | Q29616043 | ||
| Genome-scale CRISPR-Cas9 knockout screening in human cells | Q29616044 | ||
| Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1 | Q29616092 | ||
| Genetic screens in human cells using the CRISPR-Cas9 system | Q29617411 | ||
| Decay characteristics of HIV-1-infected compartments during combination therapy | Q29619375 | ||
| Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage | Q33783714 | ||
| Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection | Q33854184 | ||
| Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases | Q33886716 | ||
| CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission | Q34108023 | ||
| RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma | Q34121209 | ||
| Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo | Q34124290 | ||
| A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team | Q34438252 | ||
| Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9 | Q34727851 | ||
| DNA double-strand break repair by homologous recombination | Q34835417 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | CRISPR | Q412563 |
| Cas9 | Q16965677 | ||
| CRISPR-Cas method | Q17310682 | ||
| P304 | page(s) | 15577 | |
| P577 | publication date | 2015-10-20 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection | |
| P478 | volume | 5 |
| Q90071246 | A Broad Application of CRISPR Cas9 in Infectious Diseases of Central Nervous System |
| Q29994612 | A CRISPR toolbox to study virus-host interactions |
| Q36408534 | A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220. |
| Q42289775 | A One-Step PCR-Based Assay to Evaluate the Efficiency and Precision of Genomic DNA-Editing Tools. |
| Q89792530 | A whole-tissue RNA-seq toolkit for organism-wide studies of gene expression with PME-seq |
| Q96431392 | Abrogation of PRRSV infectivity by CRISPR-Cas13b-mediated viral RNA cleavage in mammalian cells |
| Q46208205 | Addressing challenges in the clinical applications associated with CRISPR/Cas9 technology and ethical questions to prevent its misuse |
| Q38691942 | Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9. |
| Q64060697 | Application of CRISPR/Cas9-Based Gene Editing in HIV-1/AIDS Therapy |
| Q34539796 | Applications of CRISPR technologies in research and beyond |
| Q89399006 | Broad-Spectrum and Personalized Guide RNAs for CRISPR/Cas9 HIV-1 Therapeutics |
| Q64923390 | CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4+ T cells and hematopoietic stem/progenitor cells promotes HIV-1 resistance and CD4+ T cell enrichment in humanized mice. |
| Q58765254 | CCR5del32 genotype in human enteroviral cardiomyopathy leads to spontaneous virus clearance and improved outcome compared to wildtype CCR5 |
| Q38688945 | CRISPR Editing Technology in Biological and Biomedical Investigation. |
| Q55383943 | CRISPR therapeutic tools for complex genetic disorders and cancer (Review). |
| Q99557785 | CRISPR-Based Diagnosis of Infectious and Noninfectious Diseases |
| Q39014648 | CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes |
| Q47553089 | CRISPR-Cas Targeting of Host Genes as an Antiviral Strategy |
| Q40100879 | CRISPR-Cas based antiviral strategies against HIV-1. |
| Q40299079 | CRISPR-Cas9 system-driven site-specific selection pressure on Herpes simplex virus genomes |
| Q38822073 | CRISPR-Cas9 technology and its application in haematological disorders |
| Q47161696 | CRISPR/Cas9 Genome-Editing System in Human Stem Cells: Current Status and Future Prospects. |
| Q57493121 | CRISPR/Cas9 System: A Bacterial Tailor for Genomic Engineering |
| Q47549689 | CRISPR/Cas9-Advancing Orthopoxvirus Genome Editing for Vaccine and Vector Development |
| Q64073285 | CRISPR/Cas9-Based Antiviral Strategy: Current Status and the Potential Challenge |
| Q36196813 | CRISPR/Cas9-The ultimate weapon to battle infectious diseases? |
| Q40657354 | CRISPR/Cas9: a double-edged sword when used to combat HIV infection |
| Q55333943 | Cell Line Techniques and Gene Editing Tools for Antibody Production: A Review. |
| Q38794293 | Cell and gene therapy strategies to eradicate HIV reservoirs |
| Q53695354 | Controlling ticks and tick-borne diseases…looking forward. |
| Q38687781 | Current application of CRISPR/Cas9 gene-editing technique to eradication of HIV/AIDS. |
| Q99724691 | Delivery Approaches for Therapeutic Genome Editing and Challenges |
| Q38669948 | Developmental history and application of CRISPR in human disease |
| Q64389759 | Ectopic expression of RAD52 and dn53BP1 improves homology-directed repair during CRISPR-Cas9 genome editing |
| Q47549532 | Efficient inhibition of African swine fever virus replication by CRISPR/Cas9 targeting of the viral p30 gene (CP204L). |
| Q92871298 | Elimination of infectious HIV DNA by CRISPR-Cas9 |
| Q58694793 | Engineering CAR-T Cells for Improved Function Against Solid Tumors |
| Q39037477 | Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials |
| Q60315850 | Functional Interrogation of Primary Human T Cells via CRISPR Genetic Editing |
| Q36216276 | Gene Editing Approaches against Viral Infections and Strategy to Prevent Occurrence of Viral Escape |
| Q37136471 | Gene Editing for Treatment of Neurological Infections. |
| Q60951107 | Gene Editing of HIV-1 Co-receptors to Prevent and/or Cure Virus Infection |
| Q39227817 | Genome editing approaches: manipulating of lovastatin and taxol synthesis of filamentous fungi by CRISPR/Cas9 system |
| Q97521544 | Genome editing of CCR5 by AsCpf1 renders CD4+T cells resistance to HIV-1 infection |
| Q40042102 | Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4+ T cells from HIV-1 infection |
| Q45874506 | Genome modification of CXCR4 by Staphylococcus aureus Cas9 renders cells resistance to HIV-1 infection |
| Q52431359 | Genome scale screening identification of SaCas9/gRNAs for targeting HIV-1 provirus and suppression of HIV-1 infection. |
| Q33729598 | Genome-Edited T Cell Therapies. |
| Q37593222 | Glycosylphosphatidylinositol-Anchored Anti-HIV scFv Efficiently Protects CD4 T Cells from HIV-1 Infection and Deletion in hu-PBL Mice |
| Q92733810 | HIV Apheresis Tags (HIVAT) Aided Elimination of Viremia |
| Q55190209 | HIV-1 inhibition in cells with CXCR4 mutant genome created by CRISPR-Cas9 and piggyBac recombinant technologies. |
| Q36730743 | Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense |
| Q37638282 | Immune regulator ABIN1 suppresses HIV-1 transcription by negatively regulating the ubiquitination of Tat. |
| Q60342834 | Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts |
| Q64244878 | Involvement of CXCR4 in Normal and Abnormal Development |
| Q34047618 | Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition |
| Q59359574 | Nanotechnology approaches to eradicating HIV reservoirs |
| Q39140209 | Novel AIDS therapies based on gene editing |
| Q91344642 | Novel gRNA design pipeline to develop broad-spectrum CRISPR/Cas9 gRNAs for safe targeting of the HIV-1 quasispecies in patients |
| Q90298967 | Prediction of Human Immunodeficiency Virus Type 1 Subtype-Specific Off-Target Effects Arising from CRISPR-Cas9 Gene Editing Therapy |
| Q38761853 | Programmable Site-Specific Nucleases for Targeted Genome Engineering in Higher Eukaryotes |
| Q50878341 | Prospects for Foamy Viral Vector Anti-HIV Gene Therapy. |
| Q47697210 | RING finger protein 113A regulates C-X-C chemokine receptor type 4 stability and signaling |
| Q89659572 | Reduce and Control: A Combinatorial Strategy for Achieving Sustained HIV Remissions in the Absence of Antiretroviral Therapy |
| Q38654852 | Sophisticated Cloning, Fermentation, and Purification Technologies for an Enhanced Therapeutic Protein Production: A Review |
| Q38827119 | Stem cell-based therapies for HIV/AIDS. |
| Q94468761 | Stromal cell-derived factor 1 regulates in vitro sperm migration towards the cumulus-oocyte complex in cattle |
| Q38856090 | T-cell therapies for HIV: Preclinical successes and current clinical strategies. |
| Q38832507 | TALEN gene editing takes aim on HIV. |
| Q47370396 | TALENs-mediated homozygous CCR5Δ32 mutations endow CD4+ U87 cells with resistance against HIV‑1 infection |
| Q40105376 | Targeting a global health problem: Vaccine design and challenges for the control of tick-borne diseases |
| Q108782646 | Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition |
| Q26745923 | Targeting the latent reservoir to achieve functional HIV cure |
| Q37685690 | Technologies for Proteome-Wide Discovery of Extracellular Host-Pathogen Interactions |
| Q39260698 | The CRISPR/Cas9 system: Their delivery, in vivo and ex vivo applications and clinical development by startups |
| Q60925796 | The Impact of CRISPR-Cas System on Antiviral Therapy |
| Q90152125 | The Potential Use of the CRISPR-Cas System for HIV-1 Gene Therapy |
| Q39230418 | Therapeutic gene editing: delivery and regulatory perspectives |
| Q57493531 | Transient Retrovirus-Based CRISPR/Cas9 All-in-One Particles for Efficient, Targeted Gene Knockout |
| Q33784472 | Using nanoBRET and CRISPR/Cas9 to monitor proximity to a genome-edited protein in real-time |
| Q93184325 | Zikavirus prME Envelope Pseudotyped Human Immunodeficiency Virus Type-1 as a Novel Tool for Glioblastoma-Directed Virotherapy |
Search more.